Cardiomyocyte apoptosis and inflammation can both contribute to cardiac injury after transient ischemia, yet our understanding of the intracellular signaling pathways controlling these processes in the heart remains incomplete. Our preliminary data suggest that signaling via the Death Receptor (DR) adaptor protein, Fas-associated death domain protein (FADD), plays a critical role in both these processes in cardiomyocytes. The goals of this proposal are to define the role of FADD signaling in models of ischemia-reperfusion injury (IRI) and infarction, to identify the downstream mechanisms that mediate these effects, and to explore the potential of FADD inhibition as a therapeutic intervention. This proposal is based on three hypotheses: 1) that FADD signaling is an important determinant of the functional and anatomic consequences of IRI and infarction, 2) that distinct intracellular signaling pathways mediate FADD's effects on cardiomyocyte survival and inflammation, and that 3) the unusual ability of a dominant negative FADD to simultaneously promote cardiomyocyte survival and inhibit inflammatory signaling will mediate substantial benefits in IRI that are sustained over time. To test these hypotheses, cardiac expression of wild-type and dominant negative FADD, will be achieved through somatic gene transfer, to define the role of FADD signaling and identify potential downstream mediators in both in vitro and in vivo models of ischemia.
In Specific Aim 1, we will examine the role of FADD signaling in in vitro models of cardiomyocyte apoptosis.
In Specific Aim 2, we will define the interactions of FADD and inflammatory signaling via NF-kappaB.
In Specific Aim 3, we will evaluate the anatomic and functional consequences of FADD signaling in both acute and chronic in vivo rat models of IRI and infarction. Defining the intracellular pathways that control cardiomyocyte survival and inflammation, and learning to manipulate these pathways in the heart may provide novel therapeutic approaches for the management of ischemic heart disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL073363-02
Application #
6832781
Study Section
Cardiovascular and Renal Study Section (CVB)
Program Officer
Massicot-Fisher, Judith
Project Start
2003-12-09
Project End
2008-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
2
Fiscal Year
2005
Total Cost
$347,900
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Sosnovik, David E; Nahrendorf, Matthias; Panizzi, Peter et al. (2009) Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging 2:468-75
Zhu, Xinsheng; Zhao, Huailong; Graveline, Amanda R et al. (2006) MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol 291:H1900-9
Matsui, Takashi; Rosenzweig, Anthony (2005) Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38:63-71
Aoyama, Takuma; Matsui, Takashi; Novikov, Mikhail et al. (2005) Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 111:1652-9
Grazette, Luanda P; Rosenzweig, Anthony (2005) Role of apoptosis in heart failure. Heart Fail Clin 1:251-61
Grazette, Luanda P; Boecker, Wolfgang; Matsui, Takashi et al. (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44:2231-8